CompletedPhase 3NCT00529152

Safety and Efficacy of Ferriprox™ (Deferiprone) Oral Solution in Iron Overloaded Pediatric Patients

Studying Rare hereditary hemochromatosis

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: ApoPharma
Principal Investigator: Prof. Mohsen S El Alfy, MD
Children Hospital, Ain Shams University, Cairo, Egypt
Intervention: Deferiprone(drug)
Enrollment: 100 target
Eligibility: 10 years · All sexes
Timeline: 2007 – 2008

Study locations (4)

Abo El Reish Hospital, Cairo University, Cairo, Egypt
Children Hospital, Ain Shams University, Cairo, Egypt
Cipto Mangunkusumo National Hospital, Jakarta, Indonesia
University of Malaya Medical Center, Kuala Lumpur, Malaysia

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00529152 on ClinicalTrials.gov

Other trials for Rare hereditary hemochromatosis

Additional recruiting or active studies for the same condition.

RECRUITINGNCT05294471
Fully Automated High-Throughput Quantitative MRI of the Liver
University of Wisconsin, Madison

See all trials for Rare hereditary hemochromatosis →

← Back to all trials